In short
This article explores the ongoing clinical trials of an advanced cancer treatment using genetically modified T lymphocytes. The therapy, known as CD19.CAR T cells, targets CD19-positive lymphoid diseases such as acute lymphoblastic leukemia (ALL) and non-Hodgkin's lymphoma (NHL). These trials aim to evaluate the safety, feasibility, and effectiveness of this innovative approach in patients who have not responded to or relapsed after standard treatments.
At a glance
- Study Type
- Phase I/II integrated clinical trial
- Target Conditions
- Relapsed or refractory CD19+ lymphoid diseases (ALL, NHL, CLL, DLBCL, FL, MCL)
- Treatment
- Autologous T lymphocytes genetically modified with CD19-targeting CARs
- Primary Objectives
- Evaluate safety, feasibility of dose escalation, toxicity assessment
- Secondary Objectives
- Assess CAR T-cell survival, function, anti-tumor efficacy, patient outcomes
- Key Eligibility (Adults)
- Confirmed CD19+ disease, relapsed/refractory status, adequate organ function
- Key Eligibility (Pediatric)
- Age 3-18 years, CD19+ ALL, relapsed/refractory disease, measurable disease/MRD
- Primary Endpoints
- Toxicity assessment, CRS/ICANS evaluation, dose-limiting toxicity, cell production metrics
- Secondary Endpoints
- Response rates, survival outcomes, B-cell depletion correlation
What is this treatment?
The treatment being studied is called "T Lymphocytes Transduced with RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector," also known as CD19.CAR T cells or HD-CAR-1. This is a type of cell therapy, which means it uses specially modified cells from the patient's own body to fight disease.
How does it work?
This treatment involves taking a type of immune cell called T lymphocytes (a kind of white blood cell) from the patient's blood. These cells are then genetically modified in a laboratory using a retroviral vector. This modification equips the T cells with a special receptor called a Chimeric Antigen Receptor (CAR) that targets a protein called CD19, which is found on the surface of certain cancer cells.
The modified T cells, now called CAR T cells, are then infused back into the patient's body. These cells are designed to recognize and attack cancer cells that have the CD19 protein, potentially providing a more targeted and effective treatment for certain types of blood cancers.
What conditions does it target?
This treatment is being studied for patients with relapsed or refractory CD19+ lymphoid diseases. Specifically, it targets:
- Acute Lymphoblastic Leukemia (ALL): A type of blood and bone marrow cancer that affects white blood cells
- Non-Hodgkin's Lymphoma (NHL): A group of blood cancers that start in white blood cells called lymphocytes
- Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects blood and bone marrow
- Diffuse Large B-cell Lymphoma (DLBCL): An aggressive type of NHL
- Follicular Lymphoma (FL): A slow-growing type of NHL
- Mantle Cell Lymphoma (MCL): A rare type of NHL
"Relapsed" means the cancer has returned after treatment, while "refractory" means the cancer has not responded to treatment.
Current Clinical Trial
A clinical trial called HD-CAR-1 is currently underway to study this treatment. It is a Phase I/II trial, which means it aims to test both the safety and effectiveness of the treatment.
Who is eligible for the treatment?
The trial has different eligibility criteria for adults and children:
For Adults (18 years and older):
- Confirmed CD19+ ALL, CLL, DLBCL, FL, or MCL
- Relapsed or refractory disease (including "molecular relapse" with minimal residual disease)
- Adequate kidney function and lymphocyte count
For Children (3 to 17 years):
- Confirmed CD19+ ALL
- Relapsed or refractory disease
- Measurable disease at time of enrollment
- Life expectancy of at least 12 weeks
- Adequate performance status
There are also several exclusion criteria, such as certain ongoing infections or other medical conditions, that might prevent a person from participating in the trial.
Objectives of the Study
The main goals of this study are:
- To evaluate the safety of the treatment at different doses
- To assess how well the modified T cells survive and function in the body
- To measure how effective the treatment is in reducing cancer burden
- To track how long the treatment's effects last
- To monitor overall survival of patients after treatment
Safety Considerations
As with any new treatment, safety is a primary concern. The study will closely monitor for side effects, including:
- Cytokine Release Syndrome (CRS): A condition where the immune system becomes overly activated
- Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS): A neurological side effect that can occur with some immunotherapies
- Other potential toxicities, which will be graded according to standardized criteria
It's important to note that this is an experimental treatment still under investigation. The full range of potential benefits and risks is not yet known, which is why careful study through clinical trials is necessary.